Syncron Accelerates Growth by Joining the AWS ISV Accelerate Program
23.1.2025 14:00:00 CET | Business Wire | Press release
Syncron, a leading provider of intelligent Service Lifecycle Management solutions, announced today that it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program. This co-sell program supports AWS Partners that offer software solutions running on or integrating with AWS, connecting them with the AWS Sales organization to drive new business and accelerate sales cycles.
Unlocking New Growth Opportunities with AWS
By joining the AWS ISV Accelerate Program, Syncron gains focused co-selling support from AWS, as well as access to sales enablement resources, including educational events and solution libraries. Through this partnership, Syncron will collaborate closely with AWS Sales teams, providing better customer outcomes through its integrated and optimized cloud solutions for after-sales services.
Joining the program also enhances Syncron's visibility within the AWS ecosystem, ensuring that AWS Account Managers can actively support the promotion and sale of Syncron’s solutions, benefiting both current and prospective customers.
Claire Rychlewski, Chief Revenue Officer at Syncron, commented on Syncron’s strengthened relationship with AWS: “Being part of the AWS ISV Accelerate Program is a game-changer for Syncron. This collaboration means our solutions are now fully aligned with the AWS commitment to supporting software providers in driving innovative customer-focused outcomes. The opportunity to co-sell with AWS opens new avenues for growth and makes it easier for our customers to access our solutions directly through the AWS Marketplace.”
Through the AWS Marketplace, Syncron customers will gain numerous benefits, including a streamlined procurement process, improved licensing flexibility, and procurement efficiencies that translate into time and cost savings. Customers will also be able to leverage their existing AWS budget allocations to purchase Syncron's AI-powered service lifecycle management solutions, making it easier for organizations already working with AWS to benefit from Syncron's software offerings. Syncron's AI-powered Service Lifecycle Management (SLM) solutions help OEMs and distributors in the automotive, construction, mining, agricultural and industrial equipment, medical devices, consumer durables, high tech, aerospace and other industries successfully transition to future service-driven business models by optimizing service quality and delivery to increase customer loyalty. With more than $3 billion in annual value creation, Syncron connects and synchronizes every aspect of aftermarket service.
In just under eight months, Syncron has progressed from listing its Software as a Service (SaaS) products on AWS Marketplace to joining the ISV Accelerate Program – a notable achievement that highlights Syncron's commitment to advancing strategic partnerships and delivering value to customers worldwide.
About Syncron
Syncron helps manufacturers and distributors capitalize on the new service economy by increasing customer loyalty and optimizing aftermarket profitability. Syncron's integrated, scalable, state-of-the-art Service Lifecycle Management (SLM) cloud platform puts data at the heart of aftermarket operations to unlock service synergies, significant revenue opportunities and help companies differentiate themselves with exceptional aftermarket customer experiences. The world’s top brands trust Syncron, making it the largest privately-owned global leader in intelligent SLM SaaS solutions. For more, visit syncron.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250123527061/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom